Prediction of Future Cardiovascular Disease With an Equation to Estimate Apolipoprotein B (TNT and IDEAL)

A practical barrier to using apolipoprotein B is that it requires a dedicated test not always ordered. This study asked whether apoB could instead be estimated from the standard lipid panel and still predict risk well.

Using data from two large statin trials, the investigators showed that an equation deriving apoB from routine values (total cholesterol, HDL, triglycerides) predicted future cardiovascular events nearly as well as directly measured apoB — with essentially identical discrimination (C-statistics of 0.650 versus 0.651) and no significant difference in reclassification.

The appeal is access: if a simple calculation from existing labs captures most of apoB’s predictive value, clinicians could gain its benefit without a new test. It is a pragmatic bridge toward apoB-informed care where direct measurement is unavailable.

We rate the evidence moderate-to-strong. As a post-hoc analysis of large trials it is sound; its high clinical significance reflects the practical value of an accessible apoB estimate, though a measured apoB remains preferable where feasible.